Mumbai, Maharashtra, India, January 2026 – Gopal J Rawal has been appointed as Senior Vice President – Sales & Marketing at Glenmark Pharmaceuticals, marking a significant leadership elevation as the company accelerates its next phase of innovation-led growth in specialty and oncology portfolios across India.
In his expanded mandate, Rawal will lead national commercial strategy, market expansion and access programs, strengthening Glenmark’s position in oncology, critical care and novel therapy platforms.
Gopal J Rawal has spent over three years at Glenmark Pharmaceuticals, where he previously served as Vice President – Sales & Marketing, leading the Hospital Business Cluster across Critical Care, Oncology, Government and Corporate Institutions. During this phase, he successfully stabilized and scaled key national portfolios, significantly expanding patient access to advanced and life-saving therapies.
Under his leadership, Glenmark strengthened its oncology and specialty presence, laying the foundation for exponential growth through the launches of Tevimbra and Brukinsa. The coming year will further witness major launches including Amelortinib and Trastuzumab Rezutican, while long-term platforms such as ISB 2001 continue to be strategically built for the future.
Prior to Glenmark, Rawal served as Vice President – Head Oncology Business at Intas Pharmaceuticals, where he led national oncology strategy, portfolio expansion and institutional business development. Before that, he held leadership roles at Dr. Reddy’s Laboratories as Commercial Head – Oncology and Associate Director – Oncology, driving access programs, commercialization strategy and large oncology franchises.
His earlier career included progressive leadership positions at Bristol-Myers Squibb, where he rose from Senior Cancer Care Advisor to Regional Manager and Brand Manager, and earlier roles at Pfizer and Zydus Cadila, giving him over two decades of deep oncology and specialty pharmaceutical leadership experience.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited is a research-led global pharmaceutical organization with operations in over 80 countries and a strong focus on specialty, branded generics and OTC businesses. With robust leadership in dermatology, respiratory and oncology therapies, Glenmark continues to advance innovation through its consolidated research alliance Ichnos Glenmark Innovation (IGI), accelerating breakthrough development in oncology and biologics while advancing its ESG and sustainability commitments worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
